Preeminent Team of Medical Advisers Helps Guide New Service Offering
PHILADELPHIA, Feb. 7 /PRNewswire-USNewswire/ -- Smart Genetics today announced the planned launch of a new Alzheimer's risk assessment service with the appointment of a medical advisory board and a service agreement with one of the leading laboratory testing companies in the world.
"Our mission at Smart Genetics is to provide people with accurate information about their genetic risk, help them understand and interpret their risk and assist them in using this information to live a better life," said Julian Awad, Co-Founder and CEO. "Our Medical Advisory Board has been instrumental in the development of our new service, which will help healthy people determine their risk of developing late onset Alzheimer's."
The Smart Genetics Alzheimer's Advisory Board comprises several leading authorities in Alzheimer's disease, genetic testing and genetic counseling. The board members are:
-- Norman Relkin, M.D., Ph.D., a board-certified neurologist who graduated from Yale College and received his M.D. and Ph.D. degrees from the Albert Einstein College of Medicine. Dr. Relkin has been a physician at the New York Presbyterian Hospital - Weill Cornell Medical Center since 1987 and director of the Cornell Memory Disorders Program since 1993. He is internationally recognized for his work on Alzheimer's disease and related disorders.
-- Lindsay Farrer, Ph.D., a medical geneticist at Boston University Schools of Medicine and Public Health, where he serves as chief of the genetics program, director of the epidemiology center and as a professor of medicine, neurology, genetics and genomics, epidemiology and biostatistics.
-- W. Andrew Faucett, M.S.,C.G.C., a faculty member in the Department
of Human Genetics at a major university's School of Medicine, CET program
coordinator for the NIH Office of Rare Diseases, and has an Interagency
|SOURCE Smart Genetics|
Copyright©2008 PR Newswire.
All rights reserved